Vireo Growth (VREOF) Notes Payables (2025)
Vireo Growth (VREOF) reported Notes Payables of $200000.0 for Q4 2025, up 24.4% sequentially from $160778.0 in Q3 2025.
Vireo Growth (VREOF) Notes Payables (2025) Analysis & Trends
Vireo Growth (VREOF) has 1 years of Notes Payables data on file, last reported at $200000.0 in Q4 2025.
- For the quarter ending Q4 2025, Notes Payables changed N/A year-over-year to $200000.0; the trailing twelve-month figure through Dec 2025 stood at $200000.0 (changed N/A YoY), and the FY2025 full-year result was $200000.0, changed N/A from the prior year.
- Notes Payables rose to $200000.0 in Q4 2025, from $160778.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $200000.0 in Q4 2025 to a low of $160778.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 160,778.00 |